Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market
Seeking Alpha ·
Earnings Call Insights: Elite Pharmaceuticals (ELTP) Q4 fiscal 2026 "Total revenues for the year were $149 million" and Elite delivered "operating income was $49 million" while "operating cash flow this year was positive $23.7 million," CFO Carter Ward (CFO Carter Ward) said, adding that cash was "$29.8 million" and "long-term debt was
DYAX Investor Sentiment
Bullish (Long) 69% · Bearish (Short) 31%
359 participants
Related News
- Down 30%, Is this Artificial Intelligence (AI) Stock a Screaming Buy?
- Why General Mills Stock Jumped Today
- 5 Under-the-Radar Stocks Fueling the AI Revolution
- Oil flows through Strait of Hormuz reportedly surge past 10M bbl/day
- Greenbrier forecasts $3-$3.15 FY2026 EPS while expanding lease fleet growth strategy
- Dnotitia Unveils STAR-KV, Achieving UP to 20x KV Cache Compression, Selected as an ICML 2026 Spotlight Paper